Aphios Corp., of Woburn, Mass., said enrollment has completed in a phase I/II trial of APH-0812 for HIV latency. APH-0812 consists of a PKC modulator such as bryostatin-1 and/or an HDAC inhibitor to reactivate latent HIV reservoirs so that HIV-1 can be eliminated from the body by antiviral therapy or immunotherapy and eradicated from the patient's body.